Huge capitol raise, CEO seat vacated, earnings call in a few days. Something big on the horizon.
dbatcl
Posts
-
-
Coats vacating CEO right after huge capitol raise feeling like some type of partnership is close, sales not going as planned for Impefa, I think they know now they need to partner with a big pharma to get more coverage or on formularies. T1 addition by year end is going to require a larger sales force, and without Impefa sales to support, partnership needed or cash burn is going to be too great. I liked Lexicon in July of last years and since then there has been continuous strengthening of this company, from management to new indication potentials.
-
Big things happening this week with Lexicon! Double from here by Friday.
Tons of cash to work with and a great short, mid and long term pipeline!!
-
Lexi market cap at $400m, I see a lot of value at this level, $1B I think would even be a steal…
-
Nothing logical about this SP, if you are holding some of the 20m short shares, Zacks upgrades this to a buy, there is a 3 hour investor day scheduled in a couple days and the share price is at this level, would you not be running to buy back here? Why risk a serious run up? Logically you would think shorts would cover today and Friday, SP would jump Monday and then short again, maybe. What drove this to mid 3s a few months ago? Why with a pipeline like this is the SP under $2?
Nothing logical right now .
-
Anyone have a theory as to what drove the SP up to mid $3 a few months back, that seems to be very strange, would love to understand that more.
-
Expecting a sizable bump by Investor Day.
https://finance.yahoo.com/news/know-lexicon-lxrx-rating-upgrade-160009709.html
-
Nasdaq LXRX Buy rating with price target avg now $10, up from $7
Short interest down about 20% from 1/12 @ 25m…. 2/29 @21m
T1 approval very likely
-
T1 approval = partnership= Europe sales = huge sales catalyst
-
Once T1 is approved, they will need a partner to sell it, and with Europe already having approval, this is a huge catalyst. I see this is a game changer.
-
I see most all shorts exiting between now and April investor day. Lexi has serious legs and could easily double from here. I’m not as smart as the shorts but see what’s on the horizon and the next 6 mo look extremely promising. 4-10 price targets likely to be taken out and go higher.
-
I see most all shorts exiting between now and April investor day. Lexi has serious legs and could easily double from here. I’m not as smart as the shorts but see what’s on the horizon and the next 6 mo look extremely promising. 4-10 price targets likely to be taken out and go higher.
-
The current consensus EPS estimate is -$0.24 on $1 million in revenues for the coming quarter and -$0.86 on $26.87 million in revenues for the current fiscal year.
Only 1M? Seems low based off Q4, considering hospital formularies 6 month waiting period ended and several big plans have picked up Impefa starting Jan 1 or around there.
I expect revisions to estimate to at least double.
Am I off base?
-
Looking into my crystal ball, T1 approval in US, plus T1 already approved in Europe = partnership and huge sales upside. We have along runway here….
-
Q1 estimates feel low based on Q4, no?
-
Looking dam sexy Lexi !!
-
Yahoo shows LXRX next earning call 4/30-5/6
Anyone know where this would come from ?
If so I good with that because in all likelihood it will be a blow out. Sales inflection is happening right now to what degree not sure, so if they need another month to make that statement, all good with me….
Folks , Lexicon is ramping up , a few bump in the road perhaps but they are definitely not failing.
-
Nasdaq LXRX analyst research this morning
Buy
Price target $7
High $10 and low $4
Let’s hope they are right!!!
https://www.nasdaq.com/market-activity/stocks/lxrx/analyst-research
LXRX
LXRX
LXRX
LXRX
LXRX
LXRX
LXRX
LXRX
LXRX
LXRX
LXRX
LXRX
CLXRX
LXRX
LXRX
LXRX
LXRX
LXRX
LXRX
LXRX